Advances in the management of inflammatory bowel disease

Internal Medicine Journal

Volumn 40, Issue 4, 2010, Pages 258-264

  Grimpen, F ^a   Pavli, P ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

Crohn's disease; IBD; Review management; Ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BASILIXIMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NATALIZUMAB; SALAZOSULFAPYRIDINE; TIOGUANINE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VISILIZUMAB;

BONE MARROW TOXICITY; CLINICAL TRIAL; COLON CROHN DISEASE; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG WITHDRAWAL; ENTERITIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFECTION; INFECTION RISK; INTESTINE CANCER; LEUKOENCEPHALOPATHY; LIVER TOXICITY; MULTIPLE SCLEROSIS; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT FAILURE; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DISEASE MANAGEMENT; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 77951115912     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02163.x     Document Type: Review

References (53)

1. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 96 : 2929 2933.
2. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009 58 : 233 240.
3. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132 : 66 75 quiz 432 433.
4. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008 57 : 893 902.
5. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004 2 : 379 388.
6. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl 1 i16 35.
7. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 32 : 651 662.
8. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005 100 : 2239 2247.
9. Leung M, Piatkov I, Rochester C, Boyages SC, Leong RW. Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression. Intern Med J 2009 39 : 121 126.
10. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 713.
11. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002 16 : 1743 1750.
12. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007 5 : 209 214.
13. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
14. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
15. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476. (Pubitemid 41770166)
16. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.
17. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002 8 : 237 243.
18. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009 58 : 492 500.
19. Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 2009 29 : 308 314.
20. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007 25 : 19 37.
21. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126 : 402 413. (Pubitemid 38182297)
22. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 608. (Pubitemid 36204954)
23. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 553.
24. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005 52 : 3403 3412.
25. Colombel JF, Loftus EV, Jr., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
26. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 2285.
27. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44 : 265 267.
28. Sandborn WJ, Rutgeerts P, Reinisch W, Kornbluth A, Lichtinger S, D'Haens G et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am J Gastroenterol 2008 103 : S436.
29. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008 134 : 1861 1868.
30. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003 124 : 917 924.
31. Toruner M, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 936.
32. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 667.
33. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
34. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 333 quiz 591.
35. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56 : 1232 1239. (Pubitemid 47300424)
36. Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008 28 : 966 972.
37. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007 13 : 2328 2332. (Pubitemid 46860734)
38. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009 24 : 1252 1257.
39. Afif W, Leighton JA, Hanauer SB, Loftus EV, Jr., Faubion WA, Pardi DS et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009 15 : 1302 1307.
40. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008 28 : 1122 1126.
41. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 66 : 921 926.
42. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009 68 : 1739 1745.
43. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005 129 : 807 818.
44. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357 : 228 238.
45. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357 : 239 250. (Pubitemid 47080388)
46. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146 : 829 838.
47. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005 353 : 1912 1925.
48. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007 132 : 1672 1683. (Pubitemid 46695722)
49. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009 8 : 28 31.
50. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005 352 : 2499 2507.
51. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008 6 : 1370 1377.
52. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004 351 : 2069 2079.
53. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008 135 : 1130 1141.